Literature DB >> 11027502

Functional coupling of cyclooxygenase 1 and 2 to discrete prostanoid synthases in liver macrophages.

P Dieter1, R Scheibe, P J Jakobsson, K Watanabe, A Kolada, S Kamionka.   

Abstract

The profile of released prostanoids after addition of exogenous arachidonic acid to resident liver macrophages is different from the profile obtained in lipopolysaccharide-pretreated cells. In resident and lipopolysaccharide-pretreated cells, AA leads to a release of thromboxane B(2), prostaglandin F(2alpha), E(2), and D(2). A specifically enhanced formation of prostaglandin E(2) is obtained in lipopolysaccharide-pretreated cells. Resident liver macrophages express cyclooxygenase 1, and thromboxane A(2)-, prostaglandin F(2alpha)-, E(2)-, and D(2)-synthase. Treatment with lipopolysaccharide induces-in addition to cyclooxygenase 2-an enhanced expression of the prostaglandin E(2) synthase. In resident liver macrophages, the formation of prostanoids from exogenous arachidonic acid is completely inhibited by SC560 (a specific inhibitor of cyclooxygenase 1), but remains unchanged with SC236 (a specific inhibitor of cyclooxygenase 2). In lipopolysaccharide-pretreated liver macrophages, the formation of thromboxane B(2), prostaglandin F(2alpha) and D(2) is equally inhibited by SC560 and SC236 by about 50%. In contrast, the formation of prostaglandin E(2) is inhibited to a greater extent by SC560 (75%) compared to SC236 (26%). We conclude from these data, that in lipopolysaccharide-pretreated liver macrophages (i) cyclooxygenase 1 and 2 couple both to discrete prostanoid synthases, (ii) the functional coupling of cyclooxygenase 1 and 2 to the thromboxane A(2)-, prostaglandin F(2alpha)-, and D(2)-synthase is almost identical, and (iii) the enhanced prostaglandin E(2) synthesis is due to an enhanced expression of the prostaglandin E(2) synthase, which is coupled more efficiently to cyclooxygenase 1. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11027502     DOI: 10.1006/bbrc.2000.3496

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  6 in total

1.  Niacin and biosynthesis of PGD₂by platelet COX-1 in mice and humans.

Authors:  Wen-Liang Song; Jane Stubbe; Emanuela Ricciotti; Naji Alamuddin; Salam Ibrahim; Irene Crichton; Maxwell Prempeh; John A Lawson; Robert L Wilensky; Lars Melholt Rasmussen; Ellen Puré; Garret A FitzGerald
Journal:  J Clin Invest       Date:  2012-03-12       Impact factor: 14.808

Review 2.  Persisting eicosanoid pathways in rheumatic diseases.

Authors:  Marina Korotkova; Per-Johan Jakobsson
Journal:  Nat Rev Rheumatol       Date:  2014-02-11       Impact factor: 20.543

3.  Distribution of constitutive (COX-1) and inducible (COX-2) cyclooxygenase in postviral human liver cirrhosis: a possible role for COX-2 in the pathogenesis of liver cirrhosis.

Authors:  N A Mohammed; S A Abd El-Aleem; H A El-Hafiz; R F T McMahon; S A El-Aleem
Journal:  J Clin Pathol       Date:  2004-04       Impact factor: 3.411

4.  Microsomal prostaglandin e synthase-1 in rheumatic diseases.

Authors:  Marina Korotkova; Per-Johan Jakobsson
Journal:  Front Pharmacol       Date:  2011-01-20       Impact factor: 5.810

Review 5.  Advances in deoxynivalenol toxicity mechanisms: the brain as a target.

Authors:  Marion S Bonnet; Julien Roux; Lourdes Mounien; Michel Dallaporta; Jean-Denis Troadec
Journal:  Toxins (Basel)       Date:  2012-11-01       Impact factor: 4.546

6.  Effects of immunosuppressive treatment on microsomal prostaglandin E synthase 1 and cyclooxygenases expression in muscle tissue of patients with polymyositis or dermatomyositis.

Authors:  M Korotkova; S Barbasso Helmers; I Loell; H Alexanderson; C Grundtman; C Dorph; I E Lundberg; P-J Jakobsson
Journal:  Ann Rheum Dis       Date:  2007-12-18       Impact factor: 19.103

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.